Erratum: Antibody specification beyond the target: Claiming a later-generation therapeutic antibody by its target epitope (Nature Biotechnology (2012) 30 (615-618) DOI: 10.1038/nbt.2291);Antibody specification beyond the target: Claiming a later-generation therapeutic antibody by its target epitope

Nature Biotechnology

Volumn 30, Issue 7, 2012, Pages 615-618

  Sandercock, Colin G ^a   Storz, Ulrich ^b  

^a Perkins Coie LLP   (United States)

^b Michalski S Hüttermann Patent Attorneys   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CD20 ANTIGEN; EPITOPE; INFLIXIMAB; OFATUMUMAB; PALIVIZUMAB; RITUXIMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CHRONIC MYELOID LEUKEMIA; DRUG TARGETING; HUMAN; PATENT; PRIORITY JOURNAL;

EID: 84863674591     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1212-1249c     Document Type: Erratum

References (11)

1. Centocor Ortho Biotech, Inc. v. Abbott Laboratories, 636 F.3d 1341 (Fed. Cir. 2011).
2. Id. p. 1348.
3. Id. pp. 1349-1350.
4. Id. p. 1353.
5. US District Court for the Southern District of California; 10-CV-00608 BEN (GS), 18 October 2011 (claim construction order dkt. no. 60).
6. Id. p. 6.
7. Id. p. 14.
8. Noelle v. Lederman, 355 F.3d 1343 (Fed. Cir. 2004); 2004 US App. LEXIS 774.
9. European Patent Office Technical Board decision T0542/95, 1999, European Patent Office Board of Appeal decisions database no. T0542/95.
10. Storz, U. IP issues of therapeutic antibodies. in SpringerBriefs in Biotech Patents 2012 (ed. Storz, U.) 1-12 (Springer, 2012).
11. See, for example, Abbott Biotechnology Ltd. v. Centocor Ortho Biotech Inc., 09cv40089, US District Court for the District of Massachusetts (Worcester); Abbott Labs. v. Bayer Healthcare, LLC, case no. 09-40002-FDS (D. Mass. 25 October 2010); and Bayer Healthcare, LLC v. Centocor Ortho Biotech, Inc., case no. 4:09-cv-11362-FDS (D. Mass. 23 December 2010).